ImmunityBio is a San Diego-based clinical stage immunotherapy company with 628 employees, focusing on therapies for urologic cancers and infectious diseases. Its lead product candidate, Anktiva, is an IL-15 superagonist fusion protein.
ImmunityBio (IBRX) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, ImmunityBio's actual EPS was -$0.09, beating the estimate of -$0.20 per share, resulting in a 55.88% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
